Skip to main content

Advertisement

SpringerLink
Log in

Risks and side effects of islet transplantation

  • Published:
Current Diabetes Reports Aims and scope Submit manuscript

Abstract

Islet transplantation can deliver stable glycemic control, relief from recurrent severe hypoglycemia, and insulin independence. Accessing the portal vein via the percutaneous hepatic approach carries the risk of bleeding, and the infusion of islets a risk of portal vein thrombosis. In the long term, common minor problems with immunosuppression are mouth ulcers, diarrhea, and acne. Longer-term risks include malignancy and serious infection, both rare to date in clinical islet transplantation. Sensitization to donor antigens may also occur. The long-term diabetes complications may stabilize, but of this aspect little is known to date. In the short term, there may be some elevation of serum cholesterol and blood pressure, in some patients there has been a decline in renal function, and in a few, acute retinal bleeds. For most, improvement in glucose control with resolution of glycemic lability and hypoglycemia has been a net benefit.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Goss JA, Soltes G, Goodpastor SE, et al.: Pancreatic islet transplantation: the radiographic approach. Transplantation 2003, 76:199–203.

    Article  PubMed  Google Scholar 

  2. Owen RJ, Ryan EA, O'Kelly K, et al.: Percutaneous transhepatic pancreatic islet cell transplantation in type 1 diabetes mellitus: radiologic aspects. Radiology 2003, 229:165–170.

    Article  PubMed  Google Scholar 

  3. Hering BJ, Kandaswamy R, Harmon JV, et al.: Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody. Am J Transplant 2004, 4:390–401. Demonstrates that with careful selection of donors and recipients a single transplant may suffice to provide insulin independence.

    Article  PubMed  CAS  Google Scholar 

  4. Ryan EA, Shandro T, Green K, et al.: Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. Diabetes 2004, 53:955–962. Provides standardized measures of hypoglycemia and lability and the improvement of these after islet transplant.

    Article  PubMed  CAS  Google Scholar 

  5. Kessler L, Passemard R, Oberholzer J, et al.: Reduction of blood glucose variability in type 1 diabetic patients treated by pancreatic islet transplantation. Diabetes Care 2002, 25:2256–2262.

    Article  PubMed  CAS  Google Scholar 

  6. Shapiro AMJ, Lakey JRT, Ryan EA, et al.: Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000, 343:230–238. First use of a steroid-free protocol for islet transplantation, heralding new era in the field.

    Article  PubMed  CAS  Google Scholar 

  7. Hirshberg B, Rother KI, Digon BJ III, et al.: Benefits and risks of solitary islet transplantation for type 1 diabetes using steroid-sparing immunosuppression. Diabetes Care 2003, 26:3288–3295. Experience, both good and bad, in a center starting an islet transplant program.

    Article  PubMed  Google Scholar 

  8. Ryan EA, Lakey JRT, Rajotte RV, et al.: Clinical outcomes and insulin secretion after islet transplantation with the Edmonton Protocol. Diabetes 2001, 50:710–719.

    Article  PubMed  CAS  Google Scholar 

  9. Markmann JF, Deng S, Huang X, et al.: Insulin independence following isolated islet transplantation and single islet infusions. Ann Surg 2003, 237:741–750. Confirms that insulin independence can be obtained once adequate islet mass is transplanted.

    Article  PubMed  Google Scholar 

  10. Fiorina P, Folli F, Maffi P, et al.: Islet transplantation improves vascular diabetic complications in patients with diabetes who underwent kidney transplantation: a comparison between kidney-pancreas and kidney-alone transplantation. Transplantation 2003, 75:1296–1301.

    Article  PubMed  Google Scholar 

  11. Robertson RP: Islet transplantation as a treatment for diabetes: a work in progress. N Engl J Med 2004, 350:694–705. Excellent review of the field of islet transplantation.

    Article  PubMed  CAS  Google Scholar 

  12. Fiorina P, Folli F, Bertuzzi F, et al.: Long-term beneficial effect of islet transplantation on diabetic macro-/microangiopathy in type 1 diabetic kidney-transplanted patients. Diabetes Care 2003, 26:1129–1136. Demonstration of the benefit of long-term function of islets after transplantation in terms of vascular disease.

    Article  PubMed  Google Scholar 

  13. Ryan EA, Lakey JRT, Paty BW, et al.: Successful islet transplantation. Continued insulin reserve provides long-term glycemic control. Diabetes 2002, 51:2148–2157.

    Article  PubMed  CAS  Google Scholar 

  14. Moberg L, Johansson H, Lukinius A, et al.: Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation. Lancet 2002, 360:2039–2045.

    Article  PubMed  CAS  Google Scholar 

  15. Bertuzzi F, Grohovaz F, Maffi P, et al.: Successful transplantation of human islets in recipients bearing a kidney graft. Diabetologia 2002, 45:77–84.

    Article  PubMed  CAS  Google Scholar 

  16. Gaber AO, Chamsuddin A, Fraga D, et al.: Insulin independence achieved using the transmesenteric approach to the portal vein for islet transplantation. Transplantation 2004, 77:309–311.

    Article  Google Scholar 

  17. Weimar B, Rauber K, Brendel MD, et al.: Percutaneous transhepatic catheterization of the portal vein: A combined CT-and fluoroscopy-guide technique. Cardiovasc Intervent Radiol 1999, 22:342–344.

    Article  PubMed  CAS  Google Scholar 

  18. Walsh TJ, Eggleston JC, Cameron JL: Portal hypertension, hepatic infarction, and liver failure complication pancreatic islet autotransplantation. Surgery 1982, 91:485–487.

    PubMed  CAS  Google Scholar 

  19. Shapiro AMJ, Lakey JRT, Rajotte RV, et al.: Portal vein thrombosis after transplantation of partially purified pancreatic islets in a combined human liver/islet allograft. Transplantation 1995, 59:1060–1063.

    PubMed  CAS  Google Scholar 

  20. Rafael E, Ryan EA, Paty BW, et al.: Changes in liver enzymes after clinical islet transplantation. Transplantation 2003, 76:1280–1284.

    Article  PubMed  CAS  Google Scholar 

  21. Casey JJ, Lakey JRT, Ryan EA, et al.: Portal venous pressure changes after sequential clinical islet transplantation. Transplantation 2002, 74:913–915.

    Article  PubMed  CAS  Google Scholar 

  22. Markmann JF, Rosen M, Siegelman ES, et al.: Magnetic resonance defined periportal steatosis following intraportal islet transplantation: a functional footprint of islet graft survival? Diabetes 2003, 52:1591–1594.

    Article  PubMed  CAS  Google Scholar 

  23. Bhargava R, Senior PA, Ackerman TE, et al.: Prevalence of hepatic steatosis after islet transplantation and its relationship to graft function. Diabetes 2004, 53:1311–1317.

    Article  PubMed  CAS  Google Scholar 

  24. Clayton HA, Davies JE, Pollard CA, et al.: Pancreatectomy with islet autotransplantation for the treatment of severe chronic pancreatitis: the first 40 patients at the Leicester general hospital. Transplantation 2003, 76:92–98.

    Article  PubMed  Google Scholar 

  25. Pyzdrowski KL, Kendall DM, Halter JB, et al.: Preserved insulin secretion and insulin independence in recipients of islet autografts. N Engl J Med 1992, 327:220–226.

    Article  PubMed  CAS  Google Scholar 

  26. Robertson RP, Lanz KJ, Sutherland DE, Kendall DM: Prevention of diabetes for up to 13 years by autoislet transplantation after pancreatectomy for chronic pancreatitis. Diabetes 2001, 50:47–50.

    Article  PubMed  CAS  Google Scholar 

  27. Digon BJ III, Rother KI, Hirshberg B, Harlan DM: Sirolimusinduced interstitial pneumonitis in an islet transplant recipient. Diabetes Care 2003, 26:3191.

    Article  PubMed  Google Scholar 

  28. Johnson JA, Kotovych M, Ryan EA, Shapiro AM: Reduced fear of hypoglycemia in successful islet transplantation. Diabetes Care 2004, 27:624–625.

    Article  PubMed  Google Scholar 

  29. Eckhard M, Martin I, Eich T, et al.: Incidence of cytomegalovirus infections after immunosuppression induction in clinical islet transplantation and impact on graft function. Transplant Proc 2002, 34:1922–1924.

    Article  PubMed  CAS  Google Scholar 

  30. Tremblay F, Fernandes M, Habbab F, et al.: Malignancy after renal transplantation: incidence and role of type of immunosuppression. Ann Surg Oncol 2003, 98:785–788.

    Google Scholar 

  31. Lutz J, Heemann U: Tumours after kidney transplantation. Curr Opin Urol 2003, 13:105–109.

    Article  PubMed  Google Scholar 

  32. Euvrard S, Kanitakis J, Claudy A: Skin cancers after organ transplantation. N Engl J Med 2003, 348:1681–1691.

    Article  PubMed  Google Scholar 

  33. Dahl-Jorgensen K, Brinchmann-Hansen O, Hanssen KF, et al.: Rapid tightening of blood glucose control leads to transient deterioration of retinopathy in insulin dependent diabetes mellitus: the Oslo study. BMJ 1985, 290:811–815.

    Article  PubMed  CAS  Google Scholar 

  34. Lauritzen T, Frost-Larsen K, Larsen H-W, Deckert T: Effect of 1 year of near-normal blood glucose levels on retinopathy in insulin-dependent diabetics. Lancet 1983, 1:200–204.

    Article  PubMed  CAS  Google Scholar 

  35. Fuchsjägger-Mayrl G, Kautzky-Willer A, Kiss B, et al.: Ocular hyperperfusion following onset of intensified insulin therapy is inversely correlated with plasma endothelin-1 in type 1 diabetes. Diabetologia 2002, 45:883–889.

    Article  CAS  Google Scholar 

  36. Königsrainer A, Miller K, Steurer W, et al.: Does pancreas transplantation influence the course of diabetic retinopathy? Diabetologia 1991, 34(suppl 1):S86-S88.

    Article  PubMed  Google Scholar 

  37. Chow VCC, Pai RP, Chapman JR, et al.: Diabetic retinopathy after combined kidney-pancreas transplantation. Clin Transplant 2003, 13:356–362.

    Article  Google Scholar 

  38. Koznarova R, Saudek F, Sosna T, et al.: Beneficial effects of pancreas and kidney transplantation on advanced diabetic retinopathy. Cell Transplant 2000, 9:903–908.

    PubMed  CAS  Google Scholar 

  39. Ojo AO, Held PJ, Port FK, et al.: Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003, 349:931–940.

    Article  PubMed  CAS  Google Scholar 

  40. Perlman A, Moore J, Kim E, et al.: Clinically significant proteinuria following the administration of sirolimus to renal transplant recipients. J Am Soc Nephrol 2003, 14:645A-646A.

    Google Scholar 

  41. Jim B, Doyle A, Bloom RD: Rapamycin is associated with worsening proteinuria in transplant patients with renal injury: a report of four cases. J Am Soc Nephrol 2003, 14:65A.

    Article  Google Scholar 

  42. Fioretto P, Steffes MW, Sutherland DE, et al.: Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998, 339:69–75.

    Article  PubMed  CAS  Google Scholar 

  43. Groth CG, Backman L, Morales JM, et al.: Sirolimus (rapamycin)-based therapy in human renal transplantation. Transplantation 2002, 67:1036–1042.

    Article  Google Scholar 

  44. Trotter JF, Wachs ME, Trouillot TE, et al.: Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not with tacrolimus. Liver Transpl 2001, 7:401–408.

    Article  PubMed  CAS  Google Scholar 

  45. Fiorina P, La Rocca E, Venturini M, et al.: Effects of kidneypancreas transplantation on atherosclerotic risk factors and endothelial function in patients with uremia and type 1 diabetes. Diabetes 2001, 50:496–501.

    Article  PubMed  CAS  Google Scholar 

  46. Navarro X, Sutherland DE, Kennedy WR: Long-term effects of pancreatic transplantation on diabetic neuropathy. Ann Neurol 1997, 42:727–736.

    Article  PubMed  CAS  Google Scholar 

  47. Brendel MD, Hering B, Schulz AO, Bretzel RG: International Islet Transplant Registry Report. 1-20. Giessen, Germany: Justus-Liebig University of Giessen; 1999.

    Google Scholar 

  48. Luzi L, Perseghin G, Brendel MD, et al.: Metabolic effects of restoring partial beta-cell function after islet allotransplantation in type 1 diabetic patients. Diabetes 2001, 50:277–282.

    Article  PubMed  CAS  Google Scholar 

  49. Jaeger C, Brendel MD, Hering BJ, et al.: Progressive islet graft failure occurs significantly earlier in autoantibody-positive than in autoantibody-negative IDDM recipients of intrahepatic islet allografts. Diabetes 1997, 46:1907–1910.

    Article  PubMed  CAS  Google Scholar 

  50. Bosi E, Braghi S, Maffi P, et al.: Autoantibody response to islet transplantation in type 1 diabetes. Diabetes 2001, 50:2464–2471.

    Article  PubMed  CAS  Google Scholar 

  51. Paty BW, Ryan EA, Shapiro AMJ, et al.: Intrahepatic islet transplantation in type 1 diabetic patients does not restore hypoglycemic hormonal counterregulation or symptom recognition after insulin independence. Diabetes 2002, 51:3428–3434.

    Article  PubMed  CAS  Google Scholar 

  52. Kendall DM, Teuscher AU, Robertson RP: Defective glucagon secretion during sustained hypoglycemia following successful islet allo-and autotransplantation in humans. Diabetes 1997, 46:23–27.

    Article  PubMed  CAS  Google Scholar 

  53. Paty BW, Lanz K, Kendall DM, et al.: Restored hypoglycemic counterregulation is stable in successful pancreas transplant recipients for up to 19 years after transplantation. Transplantation 2001, 72:1103–1107.

    Article  PubMed  CAS  Google Scholar 

  54. Gupta V, Wahoff DC, Rooney DP, et al.: The defective glucagon response from transplanted intrahepatic pancreatic islets during hypoglycemia is transplantation site-determined. Diabetes 1997, 46:28–33.

    Article  PubMed  CAS  Google Scholar 

  55. Kiberd B: Estimating the benefits of solitary pancreas and islet cell transplantation in type 1 diabetes mellitus. Can J Diabetes Care 2001, 25(suppl 2):96–102.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Islet Transplant Program, 2000 College Plaza,8215 112th Street, T6G 2C8, Edmonton, Alberta, Canada

    Edmond A. Ryan MD

Authors
  1. Edmond A. Ryan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Breay W. Paty MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter A. Senior MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. M. James Shapiro MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ryan, E.A., Paty, B.W., Senior, P.A. et al. Risks and side effects of islet transplantation. Curr Diab Rep 4, 304–309 (2004). https://doi.org/10.1007/s11892-004-0083-8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11892-004-0083-8

Keywords

Search

Navigation